BTSG vs. DGX: BrightSpring Health Services vs. Quest Diagnostics Stock Comparison

Company Profile

BrightSpring Health Services (BTSG) and Quest Diagnostics (DGX) are both classified in the Health Care Services sub-industry within the broader Health Care Providers & Services industry, placing them in the closest GICS peer bucket.

Quest Diagnostics (DGX) carries decades of public-market history since December 17, 1996, while BrightSpring Health Services (BTSG) listed on January 26, 2024 — long-window comparisons have far more historical data on the DGX side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

BrightSpring Health Services (BTSG) has an aggressive beta of 1.75, indicating higher sensitivity to broad-market moves, while Quest Diagnostics (DGX) is defensive at 0.54 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both BrightSpring Health Services (BTSG) at 15.54% and Quest Diagnostics (DGX) at 15.32% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Quest Diagnostics (DGX) at 9.54% retains a top-quartile share of revenue as profit, ahead of BrightSpring Health Services (BTSG) at 2.69%, which keeps about the industry-typical share.

Quest Diagnostics (DGX) at 15.63% operates in the top operating margin quartile, ahead of BrightSpring Health Services (BTSG) at 3.81%, which runs around its industry’s norm.

Profitability Metrics

Growth

BrightSpring Health Services (BTSG) at 28.18% sits in the top revenue growth quartile, while Quest Diagnostics (DGX) at 11.78% is closer to the peer norm — faster top-line expansion for BTSG.

Only one side can be read here: Quest Diagnostics (DGX) reports EPS growth of 13.78%, ranked against its industry; BrightSpring Health Services (BTSG) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both BrightSpring Health Services (BTSG) at 1.62 and Quest Diagnostics (DGX) at 1.70 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Quest Diagnostics (DGX) at 0.80 carries an industry-typical debt-to-equity mix, while BrightSpring Health Services (BTSG) at 1.09 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

BrightSpring Health Services (BTSG) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Quest Diagnostics (DGX) reports a yield of 1.33%, ranking against industry peers normally.

BrightSpring Health Services (BTSG) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Quest Diagnostics (DGX) reports a payout of 25.10%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both BrightSpring Health Services (BTSG) at 47.62 and Quest Diagnostics (DGX) at 25.46 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

BrightSpring Health Services (BTSG) at 0.88 sits in the cheaper P/S ratio quartile while Quest Diagnostics (DGX) at 2.38 prices around its industry’s middle — BTSG costs less per dollar of sales, though read it alongside growth and margins.

Quest Diagnostics (DGX) at 3.68 is valued about in line with its industry on P/B ratio, while BrightSpring Health Services (BTSG) at 6.39 carries an above-peer premium to book — BTSG is pricier on assets.

Valuation Metrics